{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-081942","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.174104+00:00","generated_at":"2026-05-31T23:11:01.485087+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Lexeo Therapeutics appoints Tim Van Hauwermeiren, argenx CEO, to Board","bullets":["Appointment effective July 5, 2024; term expires at 2027 annual meeting.","Standard director comp: $40k annual cash, initial option for 36,000 shares, annual option for 18,000 shares.","Van Hauwermeiren is co-founder and CEO of argenx; built company to ~$25B market cap.","No arrangements or family relationships with Lexeo officers; standard indemnification agreement.","Appointed as independent, non-executive director."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-081942","json":"https://secwatch.observer/filing/0000950170-24-081942.json","markdown":"https://secwatch.observer/filing/0000950170-24-081942.md","text":"https://secwatch.observer/filing/0000950170-24-081942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/0000950170-24-081942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/lxeo-20240708.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:11:01.485087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"438895daf6","claim":"Tim Van Hauwermeiren was appointed as Director at Lexeo Therapeutics, Inc..","evidence_excerpt":"On July 5, 2024 (the “Appointment Date”), Tim Van Hauwermeiren was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/0000950170-24-081942-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}